Видео с ютуба Allogene Therapeutics

Dr. Arie Belldegrun, Co-Founder and Executive Chairman, Allogene Therapeutics

Allogeneic CAR-T Therapy: Understanding This New Approach in Myeloma Immunotherapy

Allogene Therapeutics: ALLO’s Next Big Test: June Could Change Everything

Allogene Therapeutics

Переосмысление сроков и доступа пациентов к CAR-T-терапии с помощью доктора Закари Робертса из Al...

Готовый к применению CAR T: новый прорыв в лечении рака, призванный помочь большему количеству па...

Allogene Therapeutics (ALLO) Q4 2025 Earnings | ALPHA3 Data Could Transform CAR-T for Lymphoma

Анализ акций Allogene Therapeutics | Разрыв в оценке в 200 миллионов долларов

My Takeaway from Allogene Therapeutics' Big 8-K Filing

Allogene Therapeutics: ALLO Stock Just Got DERISKED… But This Is Even Bigger

Allogene Therapeutics Make or Break Moment: Is 148% Surge Just The Beginning for ALLO Stock?

Allogene Therapeutics (ALLO): 148% Surge… But This Autoimmune Catalyst Could Be Bigger

I Bought More Than 20,503 Allogene Therapeutics Shares - Here's Why

Allogene Therapeutics Data Breakthrough… Is Now a New Entry Opportunity?

Allogene Therapeutics (ALLO): High-Risk, High-Reward Stock | Cema-cel & ALPHA3 Trial Explained

Allogene Therapeutics Recent Update on ALPHA3 Trial | Conference Call

Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts

David Chang, CEO, Allogene | Onyx @ Jefferies | London Life Sciences Week 2025

Allogeneic cell therapy isn’t dead, with Brian Culley